UroGen Pharma Ltd. Stock News

PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

UroGen Pharma Ltd. recently secured FDA approval for Zusduri, its second commercial product, which is expected to significantly boost future revenues. Analysts remain bullish, with multiple Buy ratings and price targets between $31 and $47, reflecting optimism about the company's growth trajectory. Despite growing sales, UroGen continues to post net losses and will likely require a capital rais...

UroGen Pharma Ltd. (NASDAQ:URGN ) Q2 2025 Earnings Conference Call August 7, 2025 10:00 AM ET Company Participants Christopher Degnan - Chief Financial Officer David Lin - Chief Commercial Officer Elizabeth A.

UroGen (URGN) Q2 Revenue Rises 11%

ZUSDURI™ (mitomycin) for intravesical solution now available as the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) JELMYTO® achieved net product sales of $24.2 million in Q2 2025, compared with $21.8 million in Q2 2024, representing 11% year-over-year growth $161.6 million in cash, cash equivalents an...

24-month Duration of Response (DOR) of 72.2% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%) PRINCETON, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

Conference Call and Webcast Scheduled for Thursday, August 7 th , 2025, at 10:00 AM ET PRINCETON, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

PRINCETON, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.